000061817 001__ 61817
000061817 005__ 20240122154813.0
000061817 0248_ $$2sideral$$a99901
000061817 037__ $$aART-2015-99901
000061817 041__ $$aeng
000061817 100__ $$0(orcid)0000-0001-5573-6144$$aLayunta, E.$$uUniversidad de Zaragoza
000061817 245__ $$aToll-like receptor 9 activation affects intestinal serotonin transporter activity and expression in Caco-2 cells
000061817 260__ $$c2015
000061817 5060_ $$aAccess copy available to the general public$$fUnrestricted
000061817 5203_ $$aBackground: Toll-like Receptor 9 (TLR9) is expressed mainly in the endosomal membrane of intestinal cells and mediates intestinal host-microbiota interaction. Serotonin (5-HT) is an intestinal neuromodulator involved in the intestinal immunity and homeostasis. In addition, a high level of 5-HT has been described in intestinal inflammation. 5-HT intestinal availability is mainly regulated by the serotonin transporter (SERT) expressed in enterocytes. Aim: The interaction of TLR9 with serotoninergic system remains known. Therefore, the aim of the present study was to assess the effects of TLR9 activation on SERT activity and expression. Methods: Caco-2 cells and colon from wild type (WT) and TLR9 C57BL/10 mice were used in this study. SERT activity (5-HT uptake) in Caco-2 cells and SERT expression (RT-qPCR and western blotting) in both Caco-2 cells and colon from WT and TLR9 mice, were analyzed. TLR9 mRNA and protein levels were also measured in Caco-2 cells. Results: TLR9 activation in Caco-2 cells reduced SERT activity in a MyD88 independent-way. SERT mRNA and protein level in both cell lysate and brush border membrane, were also diminished. SERT protein expression in colon of TLR9 mice resulted augmented compared with WT mice. Interestingly, activation of TLR9 in Caco-2 cells diminished TLR9 mRNA and protein in the cell lysate; however, TLR9 protein in brush border resulted increased. Conclusions: The results of this work highlight the role of TLR9 as a mediator intestinal homeostasis and/or intestinal inflammation by regulating intestinal serotoninergic system.
000061817 536__ $$9info:eu-repo/grantAgreement/ES/DGA/ARAINF-012-2008$$9info:eu-repo/grantAgreement/ES/DGA/B022-13$$9info:eu-repo/grantAgreement/ES/DGA/B105-11$$9info:eu-repo/grantAgreement/ES/DGA/B61$$9info:eu-repo/grantAgreement/ES/MICINN-FEDER/BFU2009-08149$$9info:eu-repo/grantAgreement/ES/MICINN-FEDER/BFU2010-18971
000061817 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000061817 590__ $$a4.066$$b2015
000061817 591__ $$aPHYSIOLOGY$$b13 / 83 = 0.157$$c2015$$dQ1$$eT1
000061817 592__ $$a1.654$$b2015
000061817 593__ $$aPhysiology$$c2015$$dQ1
000061817 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000061817 700__ $$aLatorre, E.
000061817 700__ $$0(orcid)0000-0003-2373-6056$$aGimeno, A.$$uUniversidad de Zaragoza
000061817 700__ $$0(orcid)0000-0002-5306-9365$$aGrasa, L.$$uUniversidad de Zaragoza
000061817 700__ $$0(orcid)0000-0001-8584-3979$$aCastro, M.$$uUniversidad de Zaragoza
000061817 700__ $$0(orcid)0000-0002-7412-2073$$aPlaza, M.A.$$uUniversidad de Zaragoza
000061817 700__ $$aPardo, J.
000061817 700__ $$aGomollón, F.
000061817 700__ $$aAlcalde, A.I.
000061817 700__ $$0(orcid)0000-0003-4758-3998$$aMesonero, J.E.$$uUniversidad de Zaragoza
000061817 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000061817 773__ $$g214, Suppl. 701 (2015), 32 [15]$$pActa Physiol.$$tActa Physiologica$$x1748-1708
000061817 8564_ $$s36644$$uhttps://zaguan.unizar.es/record/61817/files/texto_completo.pdf$$yVersión publicada
000061817 8564_ $$s121407$$uhttps://zaguan.unizar.es/record/61817/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000061817 909CO $$ooai:zaguan.unizar.es:61817$$particulos$$pdriver
000061817 951__ $$a2024-01-22-15:31:21
000061817 980__ $$aARTICLE